Research sheds light on what causes severe inflammatory bowel disease.

Published Date: 26 Apr 2023

Researchers from Cedars-Sinai have discovered a genetic variation that raises the risk of perianal Crohn's disease, the most crippling form of the condition, in susceptible individuals.

Read Full News

Latest News

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

Alcohol-Related Chronic Pancreatitis Linked to Better Outcomes Than Non-Alcohol-Related Disease

Alcohol-Related Chronic Pancreatitis Linked to Better Outcomes Than Non-Alcohol-Related Disease

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

Q4 2025 Recap: Gastroenterology News and Updates

Q4 2025 Recap: Gastroenterology News and Updates

5 Gastroenterology Headlines You Missed in December 2025

5 Gastroenterology Headlines You Missed in December 2025

Todays Updates

7 Rheumatology Headlines You Missed in October 2025 Victoria Johnson

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know Victoria Johnson

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

Unseen Symptoms: Cognitive Decline Reveals Quality-of-Life Impacts of SLE, with Carla Cuda, PhD Carla Marie Cuda, PhD

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

This Year in Medicine 2025: Recognizing Top Advances in Healthcare HCPLive Editorial Staff

Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia.

5 Rheumatology Headlines You Missed in November 2025 Victoria Johnson

This rheumatology month in review emphasizes new data from the ACR Convergence.

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT Victoria Johnson

New data support firsekibart's efficacy over colchicine for preventing acute gout flares.

Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions Victoria Johnson

A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.

Todays Updates

7 Rheumatology Headlines You Missed in October 2025 Victoria Johnson

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know Victoria Johnson

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

Unseen Symptoms: Cognitive Decline Reveals Quality-of-Life Impacts of SLE, with Carla Cuda, PhD Carla Marie Cuda, PhD

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

This Year in Medicine 2025: Recognizing Top Advances in Healthcare HCPLive Editorial Staff

Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia.

5 Rheumatology Headlines You Missed in November 2025 Victoria Johnson

This rheumatology month in review emphasizes new data from the ACR Convergence.

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT Victoria Johnson

New data support firsekibart's efficacy over colchicine for preventing acute gout flares.

Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions Victoria Johnson

A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.

Latest News

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

Alcohol-Related Chronic Pancreatitis Linked to Better Outcomes Than Non-Alcohol-Related Disease

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

Q4 2025 Recap: Gastroenterology News and Updates

5 Gastroenterology Headlines You Missed in December 2025

News All Time

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD Abigail Brooks, MA

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

Empirical Donor Selection, 2-Dose Capsule FMT Regimen Improve C Diff Cure Rates Abigail Brooks, MA

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

ACP Releases Position Paper on Colorectal Cancer Screening, Surveillance Abigail Brooks, MA

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.

Conference Preview: American College of Gastroenterology’s 2025 Annual Scientific Meeting Abigail Brooks, MA

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

GERD Linked To Heightened Risk of New Alcohol Use Disorder Diagnosis Abigail Brooks, MA

Findings suggest having GERD incurs an 18% greater risk of a new AUD diagnosis, presenting an opportunity to discuss alcohol use with patients.

Emphasizing Bone Health Screening in GI, With Alexandria Markley, MD Alexandria Markley, MD

Markley describes the importance of monitoring bone health in patients with IBD and celiac disease and explains her research showing low screening rates.

Demographic Disparities in GLP-1 RA Trial Enrollment Raise Inclusivity, Validity Concerns Abigail Brooks, MA

Despite bearing a greater obesity burden, Black, Hispanic, and American Indian/Native individuals are underrepresented in GLP-1 RA RCTs for weight loss.

FDA Approves Single-Dose Formulation of Mirikizumab-mrkz for Ulcerative Colitis Ryan Livingston

FDA approves Omvoh (mirikizumab-mrkz) for monthly maintenance of ulcerative colitis, simplifying treatment for patients with this chronic condition.

Solidifying Dupilumab’s Role in Eosinophilic Esophagitis Care, With Evan Dellon, MD, MPH Evan Dellon, MD, MPH

Dellon reviews data from a post-hoc analysis of dysphagia and odynophagia in LIBERTY EoE TREET and a pooled analysis of endoscopic improvement in 2 trials.

Recommended News For You

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

For relapsed or resistant DLBCL, odronextamab produced positive results.

AI is useful in low-resource areas for triaging breast masses.

Recently released national data on drug use and abuse among Americans.

The Effect of Common Steroids on Cancer Treatments.

Basal stem-like cells identified as origin of small cell lung cancer in lab models

New research points out a promising strategy for treating metastatic medulloblastoma

Recommended Articles For You

The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease  

The Latest Research on Chronic Granulomatous Disease and Promising New Treatments  

The New Era of Oncology: Key Updates and Clinical Insights 

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Patients face high out-of-pocket costs after incident cancer diagnosis

2.

In a study, immune detection of oral cancers is linked to obesity.

3.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Common intracellular toxin could help fight leukemia

1.

Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options 

2.

The Latest Research on Chronic Granulomatous Disease and Promising New Treatments 

3.

Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources

4.

Florinef: Understanding Its Uses and Side Effects 

5.

Uncovering the Subtle Signs of Leukemia: A Guide to Early Detection

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

2.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

3.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot